Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9863949
SERIAL NO

14292613

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • NEKTAR THERAPEUTICS

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brew, Christine Taylor Pacifica, US 10 68
Davis, Darren W Houston, US 6 23
Fry, Dennis G Pacifica, US 13 93
Harrison, Stephen David Albany, US 4 6
Hoch, Ute San Francisco, US 8 14

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 9, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 9, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00